MTFBのニュース
Motif Bio PLC - Voluntary delisting from the NASDAQ Capital Market - Vox Markets 2019/12/10 07:00:00 VOX Markets
RNS Number: 2765 W Motif Bio PLC 10 December 2019. Confirmation of timing of voluntary delisting from the NASDAQ Capital Market. Motif Bio plc announces that in furtherance of the previously announced voluntary de-listing from the NASDAQ Capital Market for the Company's American Depository Shares, the Company has filed Form 25 with the US Securities and…
Hedge Funds Have Never Been More Bullish On Motif Bio plc (MTFB) 2019/11/30 14:40:06 Yahoo Finance
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on
MOTIF BIO PLC/S (NASDAQ:MTFB) Sees Large Volume Increase 2019/11/16 02:21:20 Modern Readers
MOTIF BIO PLC/S (NASDAQ:MTFB) shares saw unusually-high trading volume on Friday . Approximately 7,264 shares traded hands during trading, a decline of 99% from the previous session’s volume of 695,062 shares.The stock last traded at $0.16 and had previously closed at $0.17. MTFB has been the subject of a number of research reports. ValuEngine raised […]
Motif Bio reaches settlement with former clinical research organisation 2019/11/11 16:31:41 Share Cast
Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.
The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut 2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.